Unlock instant, AI-driven research and patent intelligence for your innovation.

Serotonergic agents with long-acting in vivo effects

a serotonergic agent and in vivo technology, applied in the field of serotonergic agents with long-acting in vivo effects, can solve problems such as schizophrenia and alzheimer's disease treatmen

Inactive Publication Date: 2005-09-15
WYETH LLC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

These compounds demonstrate half-lives measured in days rather than hours, enabling administration as infrequently as once every seven to fourteen days, effectively treating chronic CNS disorders, cognitive deficits, anxiety, and other conditions with prolonged therapeutic effects.

Problems solved by technology

Treatment of disorders such as schizophrenia and Alzheimer's disease and other chronic CNS conditions are problematic in that strict compliance is important and often requires the aid of a caretaker.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Serotonergic agents with long-acting in vivo effects
  • Serotonergic agents with long-acting in vivo effects
  • Serotonergic agents with long-acting in vivo effects

Examples

Experimental program
Comparison scheme
Effect test

example 1

1-Methyl-cyclohexanecarboxylic acid {(1R)-1-cyclohexylmethyl-2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl}-amide hydrochloride hydrate

[0033] To a solution of 0.30 g (0.91 mmol) of {(1R)-1-cyclohexylmethyl-2-[4-(2-methoxyphenyl)-piperazin-1-yl]-ethyl}-amine and 0.25 mL (1.74 mmol) of triethyl-amine in 10 mL of dichloromethane at 0° C. was added dropwise 0.16 g (1.00 mmol) of 1-methylcyclohexane-carboxylic acid chloride in 4 mL of dichloromethane. The reaction mixture was allowed to stir under nitrogen at 0° C. for one hour, and was then concentrated on a rotary evaporator, diluted with ethyl acetate and washed with saturated aqueous NaHCO3 and brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated on a rotary evaporator to yield the crude product, which was purified by flash chromatography on silica gel (dichloro-methane / methanol) and then converted to the hydrochloride.hydrate salt of the title compound with ethanolic HCl to yield 0.30 g (63%) ...

example 2

[Methoxy-3H]-1-Methyl-cyclohexanecarboxylic acid {(1R)-1-cyclohexylmethyl-2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl}-amide hydrochloride hydrate

[0035] Sodium hydride is added to a solution of 1-Methyl-cyclohexanecarboxylic acid {(1R)-1-cyclohexylmethyl-2-[4-(2-hydroxyphenyl)-piperazin-1-yl]-ethyl}-amide in DMF and the solution is stirred at room temperature under nitrogen for 2 hours. [3H] methyl iodide is added to the reaction mixture which is stirred at room temperature for 1.5 hours. The reaction mixture is pumped to dryness on the manifold and taken to dryness several times with ethanol.

example 3

[Methoxy-11C]1-Methyl-cyclohexanecarboxylic acid {(1R)-1-cyclohexylmethyl-2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl}-amide hydrochloride hydrate

[0036] In a suitable manifold, sodium hydride is added to a solution of 1-Methyl-cyclohexanecarboxylic acid {(1R)-1-cyclohexylmethyl-2-[4-(2-hydroxy-phenyl)-piperazin-1-yl]-ethyl}-amide in dimethylformamide under nitrogen. [11C]-methyl iodide is distilled into the reaction mixture and the reaction is heated to 80° C. for 5 minutes. After purification by HPLC the material is formulated for i.v. injection by dissolution in normal saline and sterile millipore filtration.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
acid additionaaaaaaaaaa
pharmaceutically acceptable acidaaaaaaaaaa
optically activeaaaaaaaaaa
Login to View More

Abstract

Compounds of the formula have a long duration of action and are useful for the treatment of chronic diseases resulting from the dysfunction of the serotonergic 5-HT1A system, such as schizophrenia and other psychotic disorders such as paranoia and mano-depressive illness.

Description

[0001] This application is a divisional of application Ser. No. 10 / 734,882, filed on Dec. 12, 2003, which is a divisional of application Ser. No. 10 / 114,577, filed on Apr. 2, 2002, which claims priority from provisional application Ser. No. 60 / 281,542, filed on Apr. 4, 2001, the entire disclosure of which is hereby incorporated by reference.[0002] This invention relates to serotonergic agents with long-acting in vivo effects, to processes for preparing them, methods of treatment using them and pharmaceutical compositions containing them. BACKGROUND OF THE INVENTION [0003] Treatment of disorders such as schizophrenia and Alzheimer's disease and other chronic CNS conditions are problematic in that strict compliance is important and often requires the aid of a caretaker. Ways of increasing compliance which would aid the patient and caretakers and are greatly desirable. [0004] WO 99 / 65887 discloses compounds of the broad genus of formula A: which include compounds where: [0005] X is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61P13/02A61P25/00A61P25/18A61P25/32C07D295/125
CPCC07B2200/05C07D295/125C07C2101/14A61P13/02A61P25/00A61P25/18A61P25/32C07C2601/14
Inventor CHILDERS, WAYNE E.KELLY, MICHAEL G.SCHECHTER, LEE E.ROSENZWEIG-LIPSON, SHARON J.
Owner WYETH LLC